Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 20...(103.1 102.6 Effect of dilutive s...),Health

Date:4/30/2009

103.1 102.6 Effect of dilutive securities: Conversion of CODES 14.4 14.4 Dilutive share-based compensation arrangements 0.7 0.4 --- --- Diluted weighted average common shares outstanding 118.2 117.4 ===== ===== (1) Includes accelerated depreciation charges. The following table presents a reconciliation of reported net income for the three months ended March 31, 2009 and 2008 to adjusted EBITDA: Table 5 Watson Pharmaceuticals, Inc. Adjusted EBITDA Reconciliation Table (Unaudited; in millions) Three Months Ended March 31, ---- ---- 2009 2008 ---- ---- GAAP net income $49.1 $50.6 Plus: Interest expense 4.7 6.8 Interest income (2.0) (2.3) Provision for income taxes 30.9 31.2 Depreciation (includes accelerated depreciation) 23.2 21.8 Amortization 21.8 20.2 ---- ---- EBITDA 127.7 128.3 ----- -----
'/>"/>

SOURCE Watson Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds